Related Experiment Videos
Update on the pharmacological management of congestive heart failure
1British Hospital, Lisboa.
Insights
Heart failure (HF) management faces challenges despite advances. Optimizing drug combinations, particularly for diastolic dysfunction, remains crucial for improving patient outcomes and reducing high mortality rates.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) incidence is rising globally.
- Despite pharmacological advances, HF mortality remains high, comparable to cancer.
- Etiologies of HF differ, with coronary artery disease and hypertension prevalent in Western societies, and valvular heart disease in underdeveloped regions.
Purpose of the Study:
- To review current pharmacological therapies for heart failure.
- To highlight the challenges in treating diastolic dysfunction compared to systolic dysfunction.
- To discuss the evolution of HF pharmacotherapy, from digitalis to ACE inhibitors.
Main Methods:
- Literature review of pharmacological treatments for heart failure.
- Analysis of historical and current therapeutic approaches.
- Discussion of the scientific basis and clinical trial outcomes of various HF medications.
Main Results:
- Numerous HF drug development efforts have yielded limited success beyond established therapies.
- Angiotensin-converting enzyme inhibitors (ACEI) have significantly improved HF management.
- Optimal treatment strategies for diastolic dysfunction are still not well-defined.
Conclusions:
- Pharmacological therapy for HF is complex, often requiring a personalized, "artful" combination of agents.
- ACE inhibitors represent a major breakthrough in HF treatment.
- Further research is needed to optimize the treatment of diastolic dysfunction and improve overall HF outcomes.
Abstract:
The incidence of heart failure (HF) is increasing while numerous pharmacological breakthroughs have been accomplished in the last two decades. Mortality remains high and is comparable to mortality due to oncologic disease. Coronary artery disease and hypertension are the primary causes of heart failure in Western societies while valvular heart disease is a significant cause in economically underdeveloped societies. While there are many pharmacological therapies for systolic disfunction, little is known about the optimal way to treat diastolic dysfunction. Although William Withering described the properties of digitalis in 1785, two hundred years passed before a scientific trial documented its benefit in HF. Skilled dissection and probing of the molecular basis of cardiac muscle contraction led to the development of numerous compounds postulated to be more effective than digitalis, only to disappoint repeatedly in numerous trials. In contrast, ACE inhibitors (ACEI) revolutionized the management of HF and it is unlikely that another class of agents will show dramatic improvements like the ACEI. Therefore, the pharmacological therapy of HF is proving to be more an art than a science, as numerous agents have to be tuned against each other to produce an overall effect that is beneficial.